Abstract
Immune therapies aiming at the destruction of a residual tumor and inducing tumor-specific memory responses are gaining acceptance among clinicians treating head and neck squamous cell carcinoma (HNSCC). This solid tumor lends itself remarkably well to currently popular vaccination strategies. Immune suppression is a hallmark of HNSCC, and its reversal accompanied by the vaccinemediated restoration of antitumor immunity might be a promising approach to achieving improved survival of HNSCC patients. To date, few antitumor vaccines for HNSCC have been clinically evaluated. The reasons for this slow start are discussed, and the ongoing phase I clinical vaccination trials for HNSCC patients are briefly described. The emphasis is on dendritic cell (DC)-based vaccines, largely because of enhanced immunogenicity of epitopes presented by adoptively-transferred DC to responder T cells in vivo. Delivery of such antitumor vaccines in combination with conventional therapies and in the setting of a minimal residual disease to HNSCC patients takes advantage of exquisite specificity of the immune system at the time when tumor-induced suppression is reduced. Vaccine-driven generation, long-term survival and maintenance of tumor-specific immune cells are the objectives that antitumor vaccines have to realize to be clinically beneficial in HNSCC.
Keywords: Head and neck cancer, vaccines, immunization, dendritic cells, tumor escape
Current Cancer Drug Targets
Title: Anti-Tumor Vaccines in Head and Neck Cancer: Targeting Immune Responses to the Tumor
Volume: 7 Issue: 7
Author(s): Theresa L. Whiteside
Affiliation:
Keywords: Head and neck cancer, vaccines, immunization, dendritic cells, tumor escape
Abstract: Immune therapies aiming at the destruction of a residual tumor and inducing tumor-specific memory responses are gaining acceptance among clinicians treating head and neck squamous cell carcinoma (HNSCC). This solid tumor lends itself remarkably well to currently popular vaccination strategies. Immune suppression is a hallmark of HNSCC, and its reversal accompanied by the vaccinemediated restoration of antitumor immunity might be a promising approach to achieving improved survival of HNSCC patients. To date, few antitumor vaccines for HNSCC have been clinically evaluated. The reasons for this slow start are discussed, and the ongoing phase I clinical vaccination trials for HNSCC patients are briefly described. The emphasis is on dendritic cell (DC)-based vaccines, largely because of enhanced immunogenicity of epitopes presented by adoptively-transferred DC to responder T cells in vivo. Delivery of such antitumor vaccines in combination with conventional therapies and in the setting of a minimal residual disease to HNSCC patients takes advantage of exquisite specificity of the immune system at the time when tumor-induced suppression is reduced. Vaccine-driven generation, long-term survival and maintenance of tumor-specific immune cells are the objectives that antitumor vaccines have to realize to be clinically beneficial in HNSCC.
Export Options
About this article
Cite this article as:
Whiteside L. Theresa, Anti-Tumor Vaccines in Head and Neck Cancer: Targeting Immune Responses to the Tumor, Current Cancer Drug Targets 2007; 7 (7) . https://dx.doi.org/10.2174/156800907782418310
DOI https://dx.doi.org/10.2174/156800907782418310 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) Green Chemistry Approach as a Versatile Platform for Nanoparticles with Biomedical Applications
Nanoscience & Nanotechnology-Asia Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Molecular Properties and Medical Applications of Peptide Nucleic Acids
Mini-Reviews in Medicinal Chemistry Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets TGFb and its Smad Connection to Cancer
Current Genomics Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Current Pharmaceutical Design Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Radiolabeled Compounds in the Development of Cytotoxic Agents
Current Pharmaceutical Design